Products: Primary Antibodies

Anti-Cav1.2 Ca2+ channel (N263/31)

Download Full Datasheet

PRODUCT OPTIONS

Catalog #	Option	Volume	Concentration	Price*
Catalog # 75-257	Option Purified	Volume 100 µL	Concentration 1 mg/mL	Price $269.00
Catalog # 73-257	Option TC Supernatant	Volume 5 mL	Concentration Lot dependent	Price $269.00

"TC Supernatant" vs. "Purified"

TC Supernatant
Hybridoma tissue-culture supernatant (5mL) generally containing 10-50 ug/mL monoclonal antibody (clone-dependent) can be a very economical choice. Supernatant is suitable for most applications including Western Blot, immunocytochemistry, immunohistochemistry etc. For applications requiring higher antibody concentration or purity (such as immunoprecipitation, microinjection, or conjugation) it is recommended that you purchase the purified form of the antibody (supplied at 1mg/mL).

Purified mAbs
Produced by in vitro bioreactor culture of hybridoma lines followed by Protein A affinity chromatography. Purified mAbs are >90% specific antibody at 1mg/mL.

Validation Images

Overview

Brand:

NeuroMab

Antibody Type:

Monoclonal

Host Species:

Mouse

Antibody Isotype:

IgG2b

Species Reactivity:

Human Mouse Rat

Applications:

ICC WB

Immunogen:

Fusion protein amino acids 808-874 (cytoplasmic loop between repeat II and III) of rat Cav1.2 (also known as Voltage-dependent L-type calcium channel subunit alpha-1C, CACNA1C, CACH2, CACN2, CACNL1A1, CCHL1A1, Brain class C and MELC-CC, accession number Q5S007)
Mouse: 100% identity (67/67 amino acids identical)
Human: 86% identity (58/67 amino acids identical) <50% identity with other Cav1 channels

Cross Reactivity:

Does not cross-react with Cav1.3

Protein Name(s):

Voltage-dependent L-type calcium channel subunit alpha-1C (Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle) (Rat brain class C) (RBC) (Voltage-gated calcium channel subunit alpha Cav1.2)

Gene Name(s):

Cacna1c Cach2 Cacn2 Cacnl1a1 Cchl1a1

Antibody Registry ID:

Purified: AB_11000167
TC Supernatant: AB_11001554

Antibody Validation and Application Notes

This antibody has been validated using the following assays:

Western Blot:

This antibody recognizes a single immunoreactive band of expected molecular weight when used to probe lysate from COS cells overexpressing target.

This antibody recognizes a single immunoreactive band of expected molecularweight when used to probe brain lysate.

Immunocytochemistry:

This antibody shows the expected staining pattern when used to stain COS cells overexpressing target.

Expected Banding Pattern:

240 kDa

Quality Control

The following quality control assay is performed on each new lot of this antibody to ensure it meets designated performance requirements.

Each new lot of this antibody is tested to confirm that it shows the expected staining pattern when used to stain COS cells overexpressing target.

Citations and References

Perissinotti PP1, Ethington EA1, Almazan E1, Martínez-Hernández E1, Kalil J1, Koob MD2, Piedras-Rentería ES3.. (2015), 'Calcium current homeostasis and synaptic deficits in hippocampal neurons from Kelch-like 1 knockout mice..' Front Cell Neurosci.. 10.3389/fncel.2014.00444.
Perissinotti PP1, Ethington EG1, Cribbs L2, Koob MD3, Martin J4, Piedras-Rentería ES5.. (2014), 'Down-regulation of endogenous KLHL1 decreases voltage-gated calcium current density..' Cell Calcium.. 10.1016/j.ceca.2014.03.002.
Liu W1, Deng J2, Wang G1, Zhang C3, Luo X1, Yan D2, Su Q4, Liu J5.. (201), 'KCNE2 modulates cardiac L-type Ca(2+) channel..' J Mol Cell Cardiol. . 10.1016/j.yjmcc.2014.03.013.
Duan L1, Bhattacharyya BJ, Belmadani A, Pan L, Miller RJ, Kessler JA.. (2014), 'Stem cell derived basal forebrain cholinergic neurons from Alzheimer's disease patients are more susceptible to cell death..' Mol Neurodegener.. 10.1186/1750-1326-9-3.
Narayanan D1, Bulley S, Leo MD, Burris SK, Gabrick KS, Boop FA, Jaggar JH.. (2013), 'Smooth muscle cell transient receptor potential polycystin-2 (TRPP2) channels contribute to the myogenic response in cerebral arteries..' J Physiol.. 10.1113/jphysiol.2013.258319.